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Objective: To design solid self-microemulsifying drug delivery system (S-SMEDDS) of
entacapone and evaluate for its anti-Parkinson's potentials.
Methods: Solubility studies were performed in various vehicles i.e., oils, surfactants and
co-surfactants and pseudo-ternary phase diagrams were plotted to understand the
microemulsion formation region. Liquid self-microemulsifying drug delivery systems
(SMEDDS) were developed using gingelly and rice bran oil as lipid vehicles, Tween 80
and Span 20 as surfactants and glycerin, propylene glycol as co-surfactants. They were
characterized by Fourier transform infrared spectroscopy, pH, viscosity, zeta potential,
polydispersibility index and droplet size analysis and evaluated for drug content, in-vitro
release, in-vitro diffusion and ex-vivo permeation. Optimized liquid SMEDDS were
converted into S-SMEDDS by adsorption and melt granulation procedures. Character-
ization by differential scanning calorimetry, SEM, micrometrics, reconstitution property,
moisture content and evaluation by drug content, drug release kinetics and shelf-life were
performed for S-SMEDDS. Parkinsonism was induced and pharmacodynamic potentials
of S-SMEDDS were evaluated.
Results: S-SMEDDS formulation AG8 had shown the highest drug release of 90.92%
within 60 min. Pharmacodynamic studies also proved the efﬁciency of entacapone S-
SMEDDS against Parkinsonism.
Conclusions: Entacapone S-SMEDDS is an effective drug delivery system that offers
more predictable and extensive drug release with enhanced shelf-life in the treatment of
acute Parkinsonism.1. Introduction
Parkinson's disease (PD) occurs at a prevalence of 52.85 per
100000 with progressive disorder in the movements. The annualmortality rate was 2.89/100000 approximately with an average
risk rate of 8.98 deaths per year[1]. PD is due to the damage of
dopaminergic neurons in nigro-striatal pathway resulted with
dementia, depression and autonomic dysfunction. In the later
stages of the disease, the non-motor symptoms often predomi-
nate. The chief symptoms of PD involve suppression of volun-
tary movements (hypokinesia), tremor at risk, usually starting in
the hands that tend to reduce in voluntary action and muscle
rigidness[2]. The ﬁrst-line drugs used to treat PD are levodopa
(dopamine precursor), selegiline (monoamine oxidase inhibitor),
tolcapone and entacapone (catecholamine-o-methyl transferase-
inhibitors), amantadine (drugs that release dopamine), bromo-
criptine, lysuride and ropinirole (dopamine receptor agonists).
Entacapone is a catecholamine-o-methyl transferase inhibitor
belongs to Biopharmaceutics Classiﬁcation System (BCS) classe under the CC BY-NC-ND license (http://
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claimed to be less hepatotoxic. It shows 98% protein binding,
0.4–0.7 h half-life, log p of 2.8, 35% bioavailability and ex-
hibits hepatic metabolism. Its action is primarily peripheral with
shorter duration of action compared to tolcapone. The main
indication for this drug is to treat early ‘end-of-dose’ deterio-
ration as it does not cause dyskinesia[4]. Apart from this,
diarrhea, gastrointestinal problems like nausea and abdominal
pains, dry mouth were frequently occurring side effects[5].
The solubility, dissolution and bioavailability of poorly sol-
uble BCS class II and IV drugs can be improved by complex-
ation with cyclodextrins[6], micronization, solid dispersions[7],
solid mixtures and nanosuspension[8]. Development of lipid
based formulations was one among them which lured a
phenomenal attention of the researchers[9]. Enhanced
permeation, versatility of lipidic excipients, low risk proﬁle,
high market potential pulls up the lipid based formulations, an
alternative technique to administer the poorly soluble drugs
effectively[10]. Self micro-emulsifying drug delivery systems
(SMEDDS) is an efﬁcient lipid based formulation[11] that
enhances the bioavailability of hydrophobic drugs[12].
SMEDDS are isotropic, thermodynamically stable anhydrous
mixture of drug, lipids, surfactants, co-surfactants which leads
to the formation of ﬁne o/w microemulsion upon gentle agitation
when it intacts gastrointestinal ﬂuids. SMEDDS are generally
formulated as liquid dosage forms or solid dosage forms by
incorporating into soft gelatin capsules. Encapsulation of
SMEDDS in soft gelatin capsules leads to the economical
burden in the manufacturing process due to increased fabrication
expenditure[13].
Oral administration of SMEDDS enables the microemulsion
formation spontaneously in gastrointestinal tract and thereby the
formed small sized droplets present large interfacial area for the
absorption of drug at the desired site of action. In these systems,
dissolution phase can be eliminated due to presence of hydro-
phobic moiety in solution form or small lipid droplets which
maintains the drug in the dissolved state throughout its transport
to the intestinal membrane's aqueous unstirred layer[14]. When
these SMEDDS are diluted with water, they can form the
thermodynamically stable, transparent microemulsion droplets
of size <50 nm[15]. The major advantage of SMEDDS is that
the drug is maintained in dissolved form in gastrointestinal
tract throughout its period[16]. Upon oral administration,
peristaltic movements of stomach and small intestine provide
the gentle agitation needed for self-emulsiﬁcation in-vivo[17].
Despite of the advantages, SMEDDS also pose some
limitations in terms of stability aspects, formulation
methodology, possible interaction of formulation when ﬁlled
in the capsule and storage aspects like temperature and
humidity[18,19]. To overcome those potential problems, liquid
SMEDDS were incorporated into solid carrier to convert them
into solid SMEDDS (S-SMEDDS)[20]. The rationale selection
of self-emulsifying formulation is based on solubility ability in
vehicles, prediction of self emulsifying region from phase dia-
gram and microemulsion droplet size.
S-SMEDDS offer many advantages such as low economic
burden, high process control, better stability and good patient
acquiescence when compared to liquid SMEDDS[21]. The major
limitation of entacapone is its poor solubility and its minimum
dose of 200 mg administered up to 8 times a day. To circumvent
this limitation, SMEDDS becomes an effective method to reduce
the dose and frequency of entacapone administration byenhancing its solubility and bioavailability. The present study
was aimed to develop and characterize the entacapone S-
SMEDDS and also to carry out preclinical evaluation.
2. Materials and methods
2.1. Materials
Entacapone was the gratuitous of Ms. Hetero Drugs Ltd.,
Hyderabad. Double reﬁned gingelly, olive, coconut, palm,
soybean and rice bran oils were procured from market. Isopropyl
myristate, oleic acid, polyethylene glycol (PEG) 400, PEG 600,
Tween 20, Tween 80, Span 80 and Span 20 were purchased
from S.D. Fine Chemicals Ltd., Mumbai. Glycerin and propyl-
ene glycol were obtained from Merck Specialties Ltd., Mumbai.
The other chemicals of analytical grade were used in the study.
2.2. Solubility study
To the 5 mL of different vehicles like oils, surfactants and co-
surfactants, an excess quantity of entacapone was added. This
blend was equilibrated at (37 ± 1) C for 72 h. After equili-
bration, centrifugation was carried out for 20 min at 3000 r/min
and undissolved drug was removed by ﬁltration using 0.45 mm
membrane ﬁlter. Further quantiﬁcation was done by diluting the
supernatant with methanol and analyzed by UV–spectropho-
tometer (Shimadzu UV 1700).
2.3. Pseudo-ternary phase diagram construction
Pseudo-ternary phase diagrams were constructed by water
titration method using oil, surfactant, co-surfactant and water at
different possible combinations. Different ratios of oil to sur-
factant/cosurfactant were chosen in the series of 1:9 to 9:1. Then,
water was added drop wise to the mixtures of oil and surfactant/
co-surfactant of different ratios and agitation was provided using
magnetic stirring until a homogenous mixture was obtained. The
transparent mixture thus obtained were identiﬁed and considered
as microemulsions[22].
2.4. Drug loaded liquid SMEDDS formulation
Liquid SMEDDSwere formulated by using various ratios of oil
(gingelly oil, rice bran oil), surfactant (Tween 80, Span 20), co-
surfactant (propylene glycol, glycerin) and entacapone (50 mg).
Initially, drug was dissolved in oil which was further added to
surfactant and co-surfactants taken in glass vials.Gentle stirring and
vortex mixing of the components at 37 Cwas done till entacapone
was completely dissolved. The mixture was then maintained at
room temperature till its further usage for characterization[22]. The
liquid SMEDDS composition was given in Table 1.
2.5. Selection of optimized liquid SMEDDS
The liquid SMEDD formulations (G1-G16 and R1-R16)
were evaluated to estimate the drug content and drug release.
The S-SMEDDS were prepared using liquid SMEDD formula-
tions of promising drug release proﬁles. Liquid SMEDDS that
had shown promised release proﬁles were subjected to charac-
terization studies viz. pH, viscosity, globule size, zeta potential
and polydispersity index.
Table 1
The composition of liquid SMEDDS.
Formulation % Weight
of oil
Surfactant:
cosurfactant
(Smix)
Smix
ratio
% Weight
of Smix
G1 9 Tween 80: propylene
glycol
1:1 79
G2 8 1:2 65
G3 9 2:1 68
G4 6 2:3 69
G5 15 Tween 80: glycerin 1:1 60
G6 8 1:2 55
G7 15 2:1 58
G8 18 2:3 72
G9 5 Span 20: glycerin 1:1 48
G10 12 1:2 58
G11 11 2:1 48
G12 20 2:3 51
G13 9 Span 20: propylene
glycol
1:1 79
G14 9 1:2 78
G15 18 2:1 68
G16 10 2:3 80
R1 7 Tween 80: propylene
glycol
1:1 55
R2 5 1:2 50
R3 8 2:1 68
R4 8 2:3 65
R5 17 Tween 80: glycerin 1:1 68
R6 9 1:2 71
R7 11 2:1 75
R8 9 2:3 76
R9 7 Span 20: glycerin 1:1 61
R10 8 1:2 60
R11 9 2:1 71
R12 7 2:3 65
R13 8 Span 20: propylene
glycol
1:1 68
R14 5 1:2 50
R15 4 2:1 45
R16 10 2:3 80
G: Gingelly oil; R: Rice bran oil.
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2.6.1. Drug content analysis
One milliliter sample of liquid SMEDD formulations were
diluted with methanol. Entacapone in the samples was quantiﬁed
by spectrophotometrically at 310 nm after suitable dilutions.
2.6.2. In-vitro drug release studies of liquid SMEDDS
In-vitro drug release estimation of liquid SMEDDS were
carried out by United States Pharmacopoeia dissolution apparatus
type I at 50 r/min. A total of 900 mL of 0.1 mol/L HCl which was
maintained at (37 ± 0.5) C was used as the dissolution medium.
An appropriate volume of liquid SMEDDS was ﬁlled into hard
gelatin capsules of “size 0”. Under the sink conditions, 5 mL of
aliquot was withdrawn from the dissolution medium at pre-
determined regular intervals of time, and ﬁltered through 0.45 mm
nylon ﬁlter. The quantity of drug released from SMEDDS was
quantiﬁed from drug absorbance analysis at 307.5 nm.
2.6.3. Diffusion studies
Diffusion studies were executed in a Franz diffusion cell
using cellophane membrane as a barrier. The formulation was
applied on the membrane placed between donor and acceptorcompartment. Constant stirring at (37 ± 1) C was maintained by
keeping the whole set up on a thermostatic magnetic stirrer. The
aliquots were collected at periodical intervals of time up to 6 h.
The receptor compartment was set for sink condition using
phosphate buffer solution pH 7.4[23]. Ex-vivo studies were carried
out by replacing cellophane membrane with goat intestine sac.
The results were compared with that of pure drug.
2.6.4. Determination of ﬂux
The cumulative amount of drug permeated was plotted
against time and the angular coefﬁcient of that curve provides
the ﬂux (J) value. The following equation was used to calculate
the permeability coefﬁcient (Kp)[24]:
Kp = J/C
where, C being the initial concentrations of drug in the
SMEDDS formulation.
2.7. Characterization of liquid SMEDDS
2.7.1. Fourier transform infra-red spectroscopy (FTIR)
Drug and excipients compatibility was analyzed by using
attenuated total resonance (ATR) FTIR spectrophotometer
(Agilent CARY 630 ATR-FTIR). The spectra of entacapone,
gingelly oil formulations (G8, G16), rice bran oil formulations
(R8, R16) of liquid SMEDDS were recorded. A sample of
material was placed on the diamond ATR crystal and analyzed
by using Agilent resolutions pro software. Each spectrum of
sample was collected from 32 single average scans at 4 cm−1
resolution in the absorption area of 600–4000 cm−1.
2.7.2. pH and viscosity
A 10 mL liquid SMEDDS formulation was used to determine
the pH by glass membrane electrode (ELICO LI 200, Hyder-
abad, India). Brookﬁeld viscometer (spindle #63) of Middle-
boro, MA-LDLV-E model maintained at 10 r/min was used to
determine the viscosity of SMEDDS.
2.7.3. Zeta potential and droplet size analysis
Excess amount of water was added to SMEDDS taken in a
volumetric ﬂask and the ﬂask was inverted regularly for gentle
mixing that results in ﬁne emulsion formation. Zeta potential and
droplet size, polydispersity index of formed microemulsions
were determined by using zeta sizer (HSA 3000, Horiba Sci-
entiﬁc, Singapore). The formula used to calculate the poly-
dispersity index was:
ĐM = Mw/Mn
where, Mw being the weight-average molar mass and Mn being
the number-average molar mass.
2.8. Preparation of S-SMEDDS
S-SMEDDS was prepared by executing the techniques i.e.,
adsorption and melt granulation. The compositions of S-
SMEDDS are presented in Table 2.
2.8.1. Adsorption technique
Liquid SMEDDS containing entacapone was mixed with
aerosil 200 that acts as adsorbent carrier to prepare S-SMEDDS.
Table 2
The composition of S-SMEDDS by adsorption and melt granulation
methods.
Method Formulation
code
Liquid
SMEDDS
equivalent
to 50 mg
of drug
Aerosil
200
(mg)
PEG
2000
(mg)
Talc
(mg)
Adsorption AG8 G8 300 – 20
AG16 G16 300 – 20
AR8 R6 300 – 20
AR16 R12 300 – 20
Melt
granulation
MG8 G8 – 280 20
MG16 G16 – 280 20
MR8 R6 – 280 20
MR16 R12 – 280 20
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liquid SMEDDS was added drop-wise onto the carrier. After
that, for uniform distribution of individual formulation, ho-
mogenization was done using glass-pestle. Then the mixture was
passed through sieve # 80 and then little quantity of talc was
added to it and air-dried ﬁnally.
2.8.2. Melt granulation technique
Hydrophilic carrier, PEG 2000 was melted and to that molten
mass liquid SMEDDS and stir it continuously so that solidiﬁ-
cation of the mixture takes place. Then the mixture was passed
through sieve # 80 and talc was added. Both samples were stored
in a vacuum desiccator.
The above dried products containing 50 mg entacapone
equivalent were ﬁlled into “size 0” capsules. Before ﬁlling into
capsules, the powders were subjected to micromeritic proper-
ties studies like bulk density, Hausner ratio and angle of
repose[23,25].
2.9. Evaluation of S-SMEDDS
2.9.1. Reconstitution ability of S-SMEDDS
Dilution study was performed to determine the reconstitu-
tion ability of S-SMEDDS upon diluting with water that
mimics the stomach environment of oral administration. Then
50 mg of S-SMEDDS was added to 50 mL of double distilled
water maintained at 37 C taken in a beaker and stirred
continuously using magnetic stirrer. The propensity of emul-
siﬁcation and emulsion droplets formation were noted regu-
larly with respect to time. When clear emulsion was formed
after stopping of stirring, it was judged quantitatively “good”
and when turbid or milky white emulsion was formed indi-
cating drug precipitation upon dilution and it was judged as
“not good emulsion”[26].
2.9.2. Drug content
The S-SMEDDS formulations were dissolved in methanol
for 20 min and then ﬁltered using 0.45 mm nylon ﬁlter. The
ﬁltrate upon suitable dilution was used for quantiﬁcation by
spectrophotometric analysis.
2.9.3. In-vitro drug release of S-SMEDDS
Dissolution studies of S-SMEDDS were carried out United
States Pharmacopoeia type I dissolution apparatus to determinethe in-vitro drug release. A total of 900 mL of 0.1 mol/L HCl
maintained at (37.0 ± 0.5) C was used as the dissolution me-
dium and study was performed at 50 r/min. A 50 mg equivalent
of S-SMEDDS encapsulated in hard gelatin capsules of size “0”
was placed into the dissolution medium. Aliquot of 5 mL was
collected at regular intervals of time and ﬁltered. Amount of
drug released was estimated by measuring absorbance at
307.5 nm.
2.9.4. Moisture content determination
The moisture content in the S-SMEDDS was estimated by
accurately weighing 1 g of S-SMEDDS and dried at 100 C for
4 h. Then the sample was allowed to cool and weight of dried
sample was measured. The moisture content of sample is
calculated using the following equation.
% Moisture content = (Weight of wet sample − Weight of dry
sample)/Weight of dry sample × 100.
2.9.5. SEM of S-SMEDDS
The external morphology of entacapone and S-SMEDDS
formulations (AG8 and MR8) was analyzed by a scanning
electron microscope (Thermoscientiﬁc SU 1510). The formula-
tions were adhered to the brass specimen club using double
sided platinum coated electrically conductive adhesive tape for
300 s at 15 Ma.
2.9.6. Differential scanning calorimetry (DSC)
DSC analysis of entacapone and S-SMEDDS (AG8 and
MR8) was performed using Perkin Elmer PYRIS 6. The S-
SMEDDS samples were placed in the aluminum pan which was
heated over a range of 35–350 C at the rate of 10 C/min.
Nitrogen purging at a rate of 100 mL/min was done to maintain
the inert atmosphere.
2.9.7. Stability of entacapone SMEDDS
Entacapone S-SMEDDS were sealed in “0” size capsules
and kept in stability chambers at 75%, 85% and 96% relative
humidity (RH) for about 3 months. Physical and chemical
stabilities were evaluated using the samples withdrawn at 0, 1,
2 and 3 months. Phase separation, drug precipitation upon
dilution with water was evaluated to determine the physical
stability. Drug content estimation represents the chemical
stability. Shelf life of the formulations were determined using
the formula t90 = 0.1052/K in which K means ﬁrst-order rate
constant.
2.10. Pharmacodynamic evaluation
Male Albino Wistar rats (150–200 g) were housed and
acclimatized under standard laboratory conditions. They were
divided into 6 groups containing 6 rats per group. Group 1
animals which received water only were considered as posi-
tive control. Animals in Group 2 were served as negative
control and administered with chlorpromazine (CPZ) (3 mg/
kg, i.p.). Animals of Group 3 were administered with CPZ
(3 mg/kg, i.p.), L-dopa and carbidopa combination (LDC)
(10 mg/kg, i.p.); Group 4 animals received CPZ (3 mg/kg,
i.p.), LDC (10 mg/kg, i.p.) and entacapone (20 mg/kg, p.o.),
Group 5 animals received CPZ (3 mg/kg, i.p.), LDC (10 mg/
kg, i.p.), AG8 (20 mg/kg, p.o.) and Group 6 animals received
Figure 1. Solubility of entacapone in various vehicles.
A: Isopropylmyristate; B: Olive oil; C: Coconut oil; D: Palm oil; E: Rice
bran oil; F: Oleic acid; G: Sunﬂower oil; H: Soybean oil; I: Gingelly oil; J:
Propylene glycol; K: PEG 400; L: PEG 600; M: Glycerin; N: Span 20; O:
Span 80; P: Tween 20; Q: Tween 80.
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kg, p.o.).
2.10.1. Anti-Parkinson 's activity
Pharmacodynamic evaluation was carried-out by following
CPZ induced Parkinson's model for 21 days. Behavioral (cata-
lepsy score) and biochemical parameters estimations (lipid per-
oxidation, nitrite levels, reduced glutathione, catalase) were done
to support the study. All experimental procedures involving
animals were conducted in accordance to Committee for the
Purpose of Control and Supervision of Experiments on Animals
guidelines and approved by Institute Animal Ethics Committee
of the Sree Vidyanikethan College of Pharmacy, Tirupati, India
with reference No.: 930/a/06/CPCSEA.
Catalepsy score was determined by block method. Score of
0.5 is assigned when the rats fail to move about by touching or
gently pushing after placing upon the table. Total score of 1 is
allotted in the 2nd stage, for each paw (0.5) if it failed to restore
the position of front paws within 15 s after placing on 3 cm
block. In the 3rd stage a score of 2 is given, for each paw (1) if
posture retention is not attained within 15 s after placing the
front paws on 9 cm block. Cut off score for catalepsy is 3.5[27].
Lipid peroxidation, reduced glutathione, nitrite and catalase
were estimated by following Wills, Ellman, Griess reagent
assay, Beers and Sizer method, respectively. Lipid peroxidation
was analyzed from thiobarbituric acid reactive substances
(TBARS) levels. TBARS was estimated by treating the rat brain
tissue homogenate with thiobarbituric acid–trichloro acetic acid
(TBA–TCA) reagent. The homogenate mixture was heated for
15 min, then cooled and centrifuged for 10 min. The colored
supernatant was analyzed spectrophotometrically at 532 nm
against blank[28].
Reduced glutathione was estimated by following method.
In this method, the brain tissue homogenate (1 mL) was
precipitated by addition of 1 mL of 10% TCA and centri-
fuged to collect supernatant portion. The supernatant portion
was added with 4 mL of phosphate solution and 0.5 mL of
5,50-dithiobis-(2-nitrobenzoic acid) reagent and analyzed at
412 nm[29].
Increased oxidative-stress in brain can lead to brain tissue
damage and in turn produces the nitric oxide. Whereas produced
nitric oxide in turn oxidized spontaneously to yield nitrite and
nitrate. Thus nitrite levels were estimated from nitric oxide
production in this work. Brain tissue homogenate and Griess
reagent of equal volumes were incubated for 10 min and
analyzed at 548 nm to determine the nitrite levels[30].
Catalase levels were estimated based on the principle of
hydrogen peroxide decomposition by the catalase enzyme evi-
denced with the reduction of absorbance with time. In this
method, a homogeneous mixture was prepared by combining
brain tissue homogenate (0.1 mL), 50 mmol/L phosphate buffer
(1.9 mL) and 30 mmol/L hydrogen peroxide (1 mL) and its
absorbance was noted down at 240 nm initially and after 3 min.
The variation in the absorbance values was used to estimate the
catalase levels[31].
2.11. Statistical analysis
Statistical analysis of the obtained data was performed by
Kruskal Wallis ANOVA followed by Dunnet's test and P < 0.05
was set as a level of signiﬁcance.3. Results
3.1. Solubility study
As drug solubilization capacity of individual vehicle is a key
determinant for the formulation of liquid SMEDDS, solubility of
entacapone in different vehicles were tested to select the suitable
vehicles and the results are shown in Figure 1. Entacapone
exhibited maximum solubility in gingelly oil, rice bran oil (oily
phases), Tween 80, Span 20 (surfactants) and propylene glycol,
glycerin (co-surfactants) which were further selected as com-
ponents for SMEDDS formulation.3.2. Pseudo-ternary phase diagrams
The pseudo-ternary diagrams were plotted as per the com-
positions given in Table 1. Increase in the concentrations of
surfactant/co-surfactant results in the increase of microemulsion
region and their phase diagrams were represented in Figure 2.
Liquid SMEDDS were prepared by adding 50 mg of entacapone
to the oil and surfactant mixture ratio that were selected from the
pseudo-ternary phase diagram.
3.3. Evaluation of liquid SMEDDS
3.3.1. FTIR
FTIR studies of entacapone and selected liquid SMEDDS
(G8, G16, R8 and R16) were shown in Figure 3.
3.3.2. Drug content
The amount of drug present in liquid SMEDDS was
assessed by methanol dilution. The drug content of entacapone
SMEDDS was between 82% and 98% for both gingelly oil and
rice bran oil formulations. The drug content values were given
in Table 3.
3.3.3. In-vitro drug release
From the formulations 85%–95% of drug release was
observed by the end of 60 min. G8 formulation showed higher
Figure 3. Comparative FTIR spectra of entacapone and SMEDDS.
Table 3
Percent drug content of the liquid SMEDDS.
Formulation
code
% Drug
content
Formulation
code
% Drug content
G1 82.03 ± 0.64 R1 86.16 ± 0.62
G2 86.12 ± 0.32 R2 88.09 ± 0.32
G3 86.06 ± 0.48 R3 86.31 ± 0.57
G4 90.25 ± 0.59 R4 95.42 ± 0.68
G5 88.12 ± 0.46 R5 82.18 ± 0.36
G6 82.31 ± 0.43 R6 94.53 ± 0.52
G7 83.50 ± 0.58 R7 89.25 ± 0.47
G8 98.19 ± 0.26 R8 94.05 ± 0.49
G9 83.12 ± 0.43 R9 89.12 ± 0.54
G10 84.08 ± 0.32 R10 91.35 ± 0.32
G11 87.32 ± 0.48 R11 86.24 ± 0.38
G12 89.52 ± 0.36 R12 95.48 ± 0.59
G13 91.16 ± 0.27 R13 85.16 ± 0.46
G14 84.09 ± 0.62 R14 87.13 ± 0.38
G15 89.18 ± 0.57 R15 88.51 ± 0.46
G16 95.23 ± 0.32 R16 95.23 ± 0.29
Results were expressed as mean ± SD (n = 6).
Figure 2. Triplots of optimized liquid SMEDDS formulation.
A: G8; B: G16; C: R8; D: R16.
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formulation showed higher drug release of 88.24% than other
rice bran oil formulations. G8, G16, R8 and R16 had shown
maximum release of 96.63%, 94.42%, 88.24% and 86.32%,
respectively than the other formulations in 60 min. The drug
release patterns from G1-G16 and R1-R16 formulations were
illustrated in Figure 4. At the end of 30 min of dissolution study,
all liquid SMEDDS have shown 50% drug release, which in-
dicates that the microemulsions had been formed with good
globule size in range of 5–100 nm.
3.3.4. In-vitro diffusion studies
The in-vitro diffusion process revealed the amount of drug
perfusion through the membrane passively and the availability
of drug at the site of application. Study was conducted for 6 h
and the samples were analyzed at 307.5 nm. The results were
depicted in Figure 5 and Table 4.Table 4
In-vitro and ex-vivo diffusion studies for liquid SMEDDS.
Formulation In-vitro studies Ex-vivo studies
Flux
(mg/cm2/h)
Diffusion
coefﬁcient (cm/h)
Flux
(mg/cm2/h)
Permeability
coefﬁcient
(cm/h)
Entacapone 1.400 2.8 × 10−2 1.000 2.0 × 10−2
G8 2.407 4.8 × 10−2 1.881 3.7 × 10−2
G16 2.152 4.3 × 10−2 2.050 4.1 × 10−2
R8 1.964 3.9 × 10−2 1.673 3.3 × 10−2
R16 1.923 3.8 × 10−2 1.700 3.4 × 10−23.3.5. Ex-vivo studies
Permeation studies were performed to estimate the formula-
tions' capacity to cross bio-membrane. The permeation study
was conducted for 6 h and the results are shown in Figure 6. In
this study the amount of drug permeated through intestinal
membrane was more in SMEDDS formulation than that of pure
drug as per the ﬂux and permeability coefﬁcient values
demonstrated in Table 4.
3.4. Characterization of optimized liquid SMEDDS for
physical properties
3.4.1. pH and viscosity
The pH of the formulations was almost neutral i.e. 7 owing to
the exploitation of neutral and/or non-ionic excipients in the
formulation which made them suitable for oral use. The
A B C D
Figure 4. Percent of drug release of liquid SMEDDS.
A: % Drug release of liquid SMEDDS from G1-G8; B: % Drug release of liquid SMEDDS from G9-G16; C: % Drug release of liquid SMEDDS from R1-
R8; D: % Drug release of liquid SMEDDS from R9-R16.
Figure 5. Drug diffusion proﬁle of liquid SEEDDS formulations compared
with entacapone.
Figure 6. Cumulative amount of drug present surface area of SMEDDS
formulation compared with entacapone.
Table 6
Micromeritics and reconstitution time of S-SMEDDS.
Formulation Bulk density
(g/cm3)
Tapped
density (g/cm3)
Hausner
ratio
Reconstitution
time (min)
AG8 0.83 ± 0.54 0.95 ± 0.08 1.14 2.5
AG16 0.84 ± 0.48 0.94 ± 0.11 1.11 2.0
AR8 0.76 ± 0.19 0.86 ± 0.43 1.13 2.0
AR16 0.86 ± 0.22 0.89 ± 0.18 1.16 1.8
MG8 0.80 ± 0.09 0.97 ± 0.23 1.21 2.2
MG16 0.84 ± 0.12 0.94 ± 0.17 1.10 2.3
MR8 0.86 ± 0.31 0.87 ± 0.32 1.12 2.0
MR16 0.82 ± 0.45 0.96 ± 0.26 1.17 2.1
Values were expressed as mean ± SD (n = 3).
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225 cps. The pH and viscosity values were tabulated in Table 5.Table 5
Physicochemical properties of selected liquid SMEDDS.
Formulation pH Viscosity
(cps)
Droplet
size (nm)
Polydispersity
index
Zeta
potential (mV)
G8 7.1 223.20 59.7 3.274 −27.0
G16 7.2 225.03 5.3 10.000 −45.6
R8 7.0 220.12 103.0 1.963 −43.4
R16 7.1 218.15 144.2 2.963 −29.93.4.2. Droplet size and zeta potential
The droplet size, zeta potential and polydispersity index were
given in Table 5. Droplet size of the formulations exhibited aversatile range from 5.3 to 144.2 nm. Polydispersity index was
in the range of 1.963–10.000. The particle size analysis results
speciﬁed that the emulsion droplets were not distributed uni-
formly. The R16 formulation of S:CoS (2:3) ratio containing
propylene glycol as co-surfactant exhibited a large size due to its
high oil content. Zeta potential values were in the range of −27.0
to −45.6 mV in diluted form.
3.5. Evaluation of S-SMEDDS
3.5.1. Micromeritic properties
Micromeritic properties of S-SMEDDS of entacapone like
bulk, tapped density and Hausner ratio were assessed. The
adsorption technique powder had bulk density of 0.76–0.86 g/
cm3 and Hausner ratio was in the range of 1.11–1.16. The bulk
density of melt granulation S-SMEDDS was observed to be in
between 0.82 and 0.86 g/cm3 and Hausner ratio in between 1.10
and 1.21 as shown in Table 6. The angle of repose was in the
range of 28 to 34 by adsorption technique and 32 to 41 by
melt granulation techniques as shown in Figure 7.3.5.2. Reconstitution properties of S-SMEDDS
Reconstitution time for S-SMEDDS formulations ranges
from 1.8 to 2.5 min as represented in Table 6 indicating spon-
taneous microemulsion formation. Phase separation or phase
inversion of microemulsion was not evidenced after 2 h.
3.5.3. Drug content of S-SMEDDS
The drug content in AG8, AG16, AR8, AR16, MG8, MG16,
MR8 and MR16 formulations was varied between 81% and
95%. More entacapone was present in S-SMEDDS of adsorption
than S-SMEDDS of melt granulation due to higher speciﬁc
surface of aerosol 200. The AG8 formulation had the highest
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resented in Figure 7.100
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0
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% Drug content Angle of repose
Figure 7. Angle of repose and percent drug content of S-SMEDDS.3.5.4. In-vitro drug release from S-SMEDDS
Dissolution study was performed for AG8, AG16, AR8,
AR16, MG8, MG16, MR8 and MR16 S-SMEDDS formula-
tions. A highest release of 90.56% was obtained in AG8
formulation by adsorption method which in-turn composed of
glycerin as a co-surfactant followed by AG16 (86.63%), AR8
(82.48%), AR16 (80.62%). The highest release of 86.32% was
obtained with MG8 formulation of melt granulation followed by
MR8 (82.48%), MR16 (78.62%), MG16 (74.34%) and entaca-
pone (51.21%) by 60th min as depicted in Figure 8. The drug
release proﬁles from the S-SMEDDS were ﬁtted to various ki-
netic models to know their release mechanism. Correlation co-
efﬁcient value (r) was found predominant for ﬁrst-order and
Hixson–Crowell model as tabulated in Table 7, representing theFigure 8. Percent of drug release from S-SMEDDS.
Table 7
Release kinetics of optimized S-SMEDDS.
Model Adsorption
AG8 AG16 AR8
Zero order r 0.8526 0.8628 0.8556
First order r 0.9962 0.9954 0.9982
Higuchi r 0.9878 0.9899 0.9942
Peppas r 0.9228 0.9611 0.9222
Baker–Lonsdale r 0.9665 0.9732 0.9782
Erosion r 0.9816 0.9924 0.9821
Hixson–Crowell r 0.9826 0.9948 0.9912release of entacapone from S-SMEDDS followed varied release
mechanisms.
3.5.5. Moisture content
This test was performed to ﬁnd out the moisture content of S-
SMEDDS. AG8 S-SMEDDS showed moisture content as 42.0%
and MR8 formulation showed 66.6%. The moisture content
determination was done to assess the moisture content in pre-
pared S-SMEDDS.
3.5.6. SEM analysis
SEM study of entacapone, S-SMEDDS formulations AG8
and MR8 were carried out and results were evidenced that the
crystalline nature of entacapone; AG8 and AR8 were existed as
loose aggregates with smooth texture as depicted in Figure 9.Melt granulation
AR16 MG8 MG16 MR8 MR16
0.8603 0.8612 0.8432 0.8413 0.8406
0.9842 0.9886 0.9823 0.9745 0.9912
0.9876 0.9885 0.9924 0.9918 0.9826
0.9568 0.9226 0.9752 0.9825 0.9868
0.9716 0.9632 0.9428 0.9724 0.9684
0.9818 0.9762 0.9808 0.9728 0.9624
0.9918 0.9823 0.9826 0.9845 0.9910
Figure 9. SEM images of SMEDDS.
A: AG8 formulation; B: MR8 formulation.
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Figure 10. DSC thermograms of entacapone, AG8 and MR8 formulations.
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The thermographs of entacapone, AG8 and MR8 formula-
tions had shown peaks at 139 C to 293 C indicating the
variance in solid state characteristics, supporting the solubility
enhancement in SMEDDS formulations. The thermographs
depicted in Figure 10 exhibited a change in melting point of the
drug showing the effect of surfactant mixture.
3.5.8. Stability study
The stability aspects of optimized S-SMEDDS (AG8 and
MR8) were carried out at various storage conditions for 90 days
at 75%, 85% and 96% RH according to International Conference
on Harmonization guidelines. The capsules were investigated for
physical and chemical stability by observing physical integrity,
drug content and in-vitro drug release at the end of 15, 30, 60
and 90 days and the data were presented in Table 8.
3.5.9. Pharmacodynamic evaluation
Chlorpromazine induced Parkinson's model was followed
and anti-Parkinson potentials of entacapone in S-SMEDDS were
evaluated by observing the catalepsy score, lipid peroxidation,
reduced glutathione, nitrite and catalase levels and the results
were reported in Table 9.
Increase in catalepsy score was observed in Group 2 animals
that received CPZ. Signiﬁcant reduction in the catalepsy score
was noticed in all the groups (3, 4, 5 and 6) at a level ofTable 8
Stability study data of S-SMEDDS.
Conditions Formulations 15 days 30 days 60 days 90 days
Physical
appearance
75% RH AG8 Intact Intact Intact Slight elongation
MR8 Intact Intact Intact Slight elongation
85% RH AG8 Intact Intact Slight elongation Elongated
MR8 Intact Intact Slight elongation Elongated
96% RH AG8 Intact Slight elongation Elongated Elongated
MR8 Intact Slight elongation Elongated Elongated
Chemical
stability
Drug content (%)
mean ± SD (n = 3)
75% RH AG8 87.12 ± 0.59 87.22 ± 0.33 84.14 ± 0.51 83.24 ± 0.45
MR8 83.04 ± 0.37 83.17 ± 0.18 84.12 ± 0.69 83.15 ± 0.31
85% RH AG8 87.17 ± 0.56 87.11 ± 0.65 79.09 ± 0.33 75.13 ± 0.94
MR8 83.23 ± 0.54 81.07 ± 0.72 76.16 ± 0.48 75.36 ± 0.54
96% RH AG8 87.42 ± 0.37 85.16 ± 1.23 69.47 ± 0.56 64.24 ± 0.64
MR8 83.29 ± 0.15 79.22 ± 0.21 70.48 ± 0.45 63.42 ± 0.48
Drug release (%)
mean ± SD (n = 3)
75% RH AG8 90.52 ± 0.58 90.02 ± 0.08 90.42 ± 0.28 89.62 ± 0.28
MR8 80.22 ± 0.45 81.22 ± 0.11 80.12 ± 0.42 80.12 ± 0.42
85% RH AG8 90.52 ± 0.68 90.52 ± 0.78 89.27 ± 0.68 89.27 ± 0.68
MR8 80.25 ± 0.56 80.23 ± 0.12 80.10 ± 0.20 80.10 ± 0.20
96% RH AG8 90.62 ± 0.80 90.62 ± 0.08 89.24 ± 0.18 88.24 ± 0.68
MR8 81.22 ± 0.31 81.62 ± 0.16 81.08 ± 0.26 81.06 ± 0.21
Table 9
Behavioral and biochemical assessment.
Groups Catalepsy score TBARS (nmol/L/mg
of protein)
GSH (nmol/L/mg
of protein)
Nitrite (nmol/L/mg
of protein)
Catalase (mmol/L/mg
of H2O2 degraded/min)
Group 1 0.0000 ± 0.0000 27.7700 ± 0.7583 18.1500 ± 0.6489 4.5200 ± 1.0478 103.0500 ± 0.5889
Group 2 2.5800 ± 0.5147* 44.1500 ± 0.7189* 6.2400 ± 0.8946* 16.2500 ± 0.3475* 74.8700 ± 0.4821*
Group 3 1.2500 ± 0.3942*,a 37.9000 ± 0.7965*,a 10.520 0 ± 1.2470*,a 12.4800 ± 0.9473*,a 97.6100 ± 1.0415*,a
Group 4 1.0800 ± 0.9731*,a 34.2500 ± 0.6245*,a 14.9800 ± 0.5874*,a 10.530 0 ± 1.1023*,a 114.940 0 ± 0.2532*,a
Group 5 0.5800 ± 0.8327*,a,b 27.8200 ± 1.3001*,a,b 20.7400 ± 0.9127*,a,b 6.2800 ± 0.6471*,a,b 126.8500 ± 1.2133*,a,b
Group 6 0.6600 ± 0.7983*,a,b 31.5300 ± 0.8112*,a,b 16.2900 ± 0.6382*,a,b 7.0600 ± 0.8419*,a,b 121.1100 ± 0.0001
*: P < 0.05 statistically signiﬁcant compared to Group 1 (positive control); a: P < 0.05 statistically signiﬁcant compared to Group 2 (CPZ treated-
negative control); b: P < 0.05 statistically signiﬁcant compared to Group 4 (treated with pure drug-entacapone).
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in the levels of catalepsy score. Signiﬁcantly reduced TBARS
and nitrate levels and augmented glutathione and catalase levels
were observed in the groups treated with AG8 and MR8
compared to group received pure entacapone at a level of
P < 0.05. S-SMEDDS of entacapone exhibited high free radical
scavenging activity against nitric oxide and reduced the levels of
TBARS compared to pure entacapone.
4. Discussion
The preferred oils i.e. rice bran oil and gingelly oil has similar
hydrophile-lipophile balance values of 7, due to which the drug
exhibited higher solubility in them. Compared with entacapone,
all the physical mixtures showed slight change in their wave
numbers of characteristic drug peaks which are considered as
insigniﬁcant. Upon FTIR results obtained, it was conﬁrmed that
drug has not undergone any chemical interaction with
excipients.
The drug content results were evident that there was no
signiﬁcant drug loss in formulation of SMEDDS. Small amounts
of drug loss might be lost due to higher side viscosities of
SMEDDS and also due to transfer of the formulations. Due to
their submicron droplet size they could diffuse more intensively
through biomembrane. After 1 h, entire drug was expected to be
available in systemic circulation, since the drug is in the mo-
lecular form and therefore, solubility was not a criterion.
The formulations at 2:3 S:coS ratio had shown more drug
release than the other ratios of S:coS formulations due to more
concentration of surfactant which consequences signiﬁcant
interfacial tension reduction. The enhanced drug release was
referred to their higher co-surfactant concentration owing to the
liquefaction of the interfacial ﬁlm and increasing the ﬁlm ﬂex-
ibility to form globule of low size than higher surfactant for-
mulations[32]. The drug release had shown variations due to the
solubilization of surfactants and co-surfactants used. Glycerin
being a short chain alcohol, when used as a co-surfactant had
shown greater particle size reduction. Less hydrophilic glycerin
sets the hydrocarbon chains of Tween 80 to align towards oil
phase between their moieties ensuing the effective van der Waal
attraction, which forms strong and stable ﬁlm opposing coales-
cence. Propylene glycol with less –OH groups, has a constraint
in decreasing interfacial tension to remarkable low level along
with Tween 80. At higher concentrations, co-surfactant provides
more ﬂexibility to the formulations.
Diffusion study demonstrated that the amount of drug
diffused/permeated along the membrane was high in formulated
SMEDDS than that of pure drug and the results of ﬂux and
permeability coefﬁcient were tabulated as Table 4. The G8
formulation showed sustained release when compared with other
formulation and entacapone. According to results obtained, G8
had shown the enhanced permeability when compared with
other formulations and even with pure entacapone. The
improvement in diffusion and permeation was because of the
microemulsion droplets formation, which reduced the interfacial
tension owing to the presence of Tween 80 (hydrophile–lip-
ophile balance-15).
Zeta potential was found to be less as liquid SMEDDS
contain non-ionic surfactants like Tween 80 and Span 20 that
could diminish the interactions among globules by steric forces
of repulsions rather than electrokinetic approach. Negative zetapotential values of SMEDDS are due to presence of lipid phases
attributed to the stability maintenance of SMEDDS.
The outcome of micromeritic analysis indicated that they
simulate good ﬂow properties. Compared to melt granulation
technique, adsorption technique S-SMEDDS showed best results
due to the adsorbent carrier Aerosil 200. The carriers used in
melt granulation being waxy in nature consequences poor ﬂow.
Manufacturing of S-SMEDDS by melt granulation required the
addition of glidant to enhance the ﬂow overcoming the hurdles
in production arena.
The faster drug release of entacapone from S-SMEDDS might
be due to spontaneous production of microemulsion. Higher drug
release was observed for adsorption based S-SMEDDS than melt
granulation S-SMEDDS. The major reason for this was the
behavior of the carrier while contacting water. In adsorption
method based S-SMEDDS, liquid SMEDDS gets adsorbed onto
the carrier surface and lies in the voids of surface until it contacts
the water. Once liquid SMEDDS contacts with water it forms
microemulsions immediately. Whereas in melt granulation based
S-SMEDDS, the drug gets mixed up with the molten hydrophilic
carrier and solubilization of carrier is required prior to the drug
release which in turn depends on the thickness of polymer matrix.
Neither methodology nor the types of carriers used in S-
SMEDDS had signiﬁcant effect on the globule size.
The higher moisture content in MR8 formulation was due to
the hydrophilic carrier i.e. PEG 4000. The low moisture content
in AG8 formulation was due to adsorbent carrier i.e. Aerosil 200
which is in inert nature.
The S-SMEDDS' SEM images represented that they possess
smooth texture with uniform surface supporting the adsorption
of entacapone onto the carrier properly.
In the stability studies at 96% RH conditions, due to moisture
absorption by the capsule shell, they lost their integrity which
consequences a negligible drug loss that results in insigniﬁcant
weight change of capsules. Shelf-life of AG8 and MR8 was
found to be 1.75 and 1.05 years respectively. Thus S-SMEDDS
formulations proffer greater stability with enhanced shelf-life.
Entacapone is a selective reversible catecholamine-o-methyl
transferase inhibitor used in combination with levodopa. The
neuropathophysiology of Parkinsonism is related to the gener-
ation of free radicals and oxidative stress. Induction of Parkin-
sonism by CPZ led to increase in catalepsy score, lipid
peroxidation (represented as TBARS), nitrite levels and
decreased levels of glutathione and catalase. Test group animals
were treated with LDC, LDC/entacapone, LDC/AG8 and LDC/
MR8 to explore the anti-Parkinson's potentials of S-SMEDDS.
It was found from the results that S-SMEDDS formulation of
AG8 had exhibited signiﬁcant anti-Parkinson potentials when
compared to MR8 formulation and entacapone which is due an
immediate release of entacapone from S-SMEDDS prepared by
adsorption method.
Entacapone being BCS class IV category poses very poor
oral bioavailability. Liquid SMEDDS of entacapone were
designed to overcome these hurdles based on its solubility in
oil, surfactant and co-surfactant. The highest drug release was
observed from the formulations having higher co-surfactant
concentration due to the less particle size. The optimized
liquid SMEDDS based on drug release were formulated into S-
SMEDDS by employing methodologies i.e., adsorption and
melt granulation. Drug release from S-SMEDDS prepared by
adsorption method was effective compared to melt granulation
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efﬁcient in the formulation of S-SMEDDS to promote the rate
of dissolution and intestinal permeability. The drug release
from the liquid formulations is more than that of solid forms.
This could be due to the existence of drug in dispersed form at
molecular state in liquid SMEDDS whereas it was not in S-
SMEDDS. The solid forms have to undergo the dissolution
process and hence it was not instantaneous. The disadvantages
of the liquid SMEDDS, such as the phase separation and
leaching could be overcome by selecting and designing them
into the solids. The solid form of SMEDDS provided better
stability in shelf. The results were well supported by the
pharmacodynamic studies in which S-SMEDDS had proven to
be effective against Parkinsonism. In general, S-SMEDDS
present advantages with accuracy of dose, shelf-life of
formulation and more patient compliance when compared to
liquid SMEDDS. Further, S-SMEDDS formulation technolo-
gies can be forwarded for pilot scale process and be fortiﬁed
with clinical research.
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